Pekka Roivas

Pekka Roivas

Auto-generated profile, based on publicly available information

Pekka Roivas


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in bioRxiv
Verified
Preprint
Open access
KPKarolina Pavic
Karolina Pavic
PMPaola Moyano-Gómez
Paola Moyano-Gómez
PRPekka Roivas
Pekka Roivas
SKSami Kurkinen
Sami Kurkinen
HPHanna Parkkola
Hanna Parkkola
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Cancerous inhibitor of PP2A (CIP2A) supports malignant growth across several cancer types. CIP2A is also a synthetic lethal therapy target for BRCA-mutant cancers. In addition, CIP2A causes Alzheimer's disease (AD) phenotype in mice. However, it is not dispensable for normal development and growth. Therefore, CIP2A is very lucrative therapy target in cancer and AD. So far it has been unclear whether the CIP2A protein harbors any druggable pockets amenable to targeting by small molecules. Here we discover a druggable pocket adjacent to the homodimerization domain of CIP2A. Mutagenesis demonstrates that pocket impacts CIP2A homodimerization, PP2A interaction, and full-length CIP2A protein stability in cancer cells. Further, we identify Gambogenic acid (GNA) as a tool compound that directly binds to CIP2A pocket region. GNA and its derivative Gambogic acid dissociate CIP2A homodimer in vitro and cause CIP2A destabilization in cellulo. The pocket contributes to the impact of GNA on homodimerization based on the protein fragment and mutagenesis analysis. These results identify structural vulnerability on CIP2A and may facilitate development of targeted CIP2A inhibitors with broad disease applicability.

4 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
PSPankaj Kumar Singh
Pankaj Kumar Singh
PRPekka Roivas
Pekka Roivas
SPShelly Pathania
Shelly Pathania
PMPaola Moyano-Gómez
Paola Moyano-Gómez
EJElmeri Matias Jokinen
Elmeri Matias Jokinen
OPOlli T. Pentikäinen
Olli T. Pentikäinen
Targeting diseases with unmet medical needs remains a major challenge, particularly when modulating protein–protein interactions. While small molecules have traditionally been employed for such targets, their limitations have driven the development of biological modalities, including monoclonal antibodies. Macrocycles occupy an intermediate space, combining the selectivity and affinity of biologics with the favorable pharmacokinetic and manufacturability profiles of small molecules. Here, we describe a rational strategy to identify medium-sized peptide-based macrocycles as ligands for TNFα. Using a minimal set of building blocks, we identified macrocycles capable of binding TNFα, demonstrating the feasibility of this approach for an otherwise undrugged cytokine target. Expansion of this strategy through larger building-block libraries, diverse cyclization chemistries, and automated high-throughput synthesis is expected to substantially enhance discovery throughput. This work illustrates the potential of rationally designing macrocycles as targeted therapeutics.

25 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
PSPankaj Kumar Singh
Pankaj Kumar Singh
PRPekka Roivas
Pekka Roivas
SPShelly Pathania
Shelly Pathania
PMPaola Moyano-Gómez
Paola Moyano-Gómez
EJElmeri Matias Jokinen
Elmeri Matias Jokinen
OPOlli T. Pentikäinen
Olli T. Pentikäinen
Targeting diseases with unmet medical needs remains a major challenge, particularly when modulating protein–protein interactions. While small molecules have traditionally been employed for such targets, their limitations have driven the development of biological modalities, including monoclonal antibodies. Macrocycles occupy an intermediate space, combining the selectivity and affinity of biologics with the favorable pharmacokinetic and manufacturability profiles of small molecules. Here, we describe a rational strategy to identify medium-sized peptide-based macrocycles as ligands for TNFα. Using a minimal set of building blocks, we identified macrocycles capable of binding TNFα, demonstrating the feasibility of this approach for an otherwise undrugged cytokine target. Expansion of this strategy through larger building-block libraries, diverse cyclization chemistries, and automated high-throughput synthesis is expected to substantially enhance discovery throughput. This work illustrates the potential of rationally designing macrocycles as targeted therapeutics.